Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3674197013 | Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3674199011 | Carbidopa (as carbidopa monohydrate) 50 mg and levodopa 200 mg prolonged-release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has manufactured dose form | Prolonged-release oral tablet | false | Inferred relationship | Some | ||
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Is a | Product containing carbidopa and levodopa in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength numerator value | 50 | false | Inferred relationship | Some | 1 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 2 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has precise active ingredient | Carbidopa monohydrate (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has basis of strength substance (attribute) | Levodopa (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 2 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength numerator value | 200 | false | Inferred relationship | Some | 2 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has precise active ingredient | Levodopa (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has unit of presentation | Tablet (unit of presentation) | false | Inferred relationship | Some | ||
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 1 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has basis of strength substance (attribute) | Carbidopa | false | Inferred relationship | Some | 1 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 1 | |
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Is a | Product containing only carbidopa and levodopa in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet | Plays role | Antiparkinson therapeutic role | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Concept inactivation indicator reference set
REPLACED BY association reference set (foundation metadata concept)
FHIR